19636 Background: Chemotherapy induced neutropenia can significantly increase patient
morbidity and mortality and decrease the efficacy of treatment either due to a decrease in …

Purpose: Practice guidelines do not recommend the routine use of colony-stimulating factors
when there is a low risk (< 10%) of febrile neutropenia (FN). We prospectively determined …

e14510 Background: PFG should be administered 24-72 h after CTX, but there is a trend to
administer it on the same day as CTX. The aim of our systematic review and meta-analysis …

Background/Aim: This study aimed to show the trend of neutrophil counts and frequency of
febrile neutropenia after changing pegfilgrastim from 3.6 mg to 1.8 mg. Patients and …

e17697 Background: PEG-P is not indicated for administration on the same day as cytotoxic
chemotherapy administration because it induces proliferation of chemo-sensitive myeloid …

Background Pegfilgrastim is widely used for the prevention of febrile neutropenia (FN) in
patients receiving myelosuppressive chemotherapy for various types of cancer. However …

Introdução Segundo dados da Organização Mundial da Saúde (OMS), a anemia é um
indicador de má nutrição e problemas de saúde e afeta mais de 2, 9 bilhões de pessoas na …

Background: The EORTC guidelines recommend primary prophylaxis with G-CSF when the
overall risk of febrile neutropenia (FN) is≥ 20%(high risk [HR]) or if the chemotherapy FN …

Breast cancer patients treated in community practices often experience reductions in
chemotherapy relative dose intensity due to neutropenic events mainly occurring in the first …

OBJECTIVES: To compare the efficacy and safety of two filgrastim formulations for
controlling chemotherapy-induced neutropenia and to evaluate the non-inferiority of the test …